- US-listed companies
- Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc.INDP
Market cap
$11.85M
P/E ratio
Dec 31, 2021 | Dec 31, 2022 | |
Research and development | 3 | 6 |
General and administrative | 5 | 9 |
Total operating expenses | 8 | 15 |
Loss from operations | -7,729,108 | -14,910,906 |
Other income, net | 17,722 | 588,108 |
Net loss | -7,711,386 | -14,322,798 |
Net loss available to common stockholders per share of common stock, basic and diluted | - | -1.73 |
Reclassification adjustment for realized gain on marketable securities included in net loss | - | -110,002 |
Unrealized gain on marketable securities | - | 206,436 |
Comprehensive loss | - | -14,226,364 |